Sirolimus Adverse Event Profile in a Non-Clinical Trial Cohort of Heart Transplantation Patients

Karim Sallam; Geetha P. Bhumireddy; Vishnu D. Evuri; Joshua P. Abella; Francois Haddad; Hannah A. Valentine; Patricia K. Nguyen; Michael X. Pham

doi:10.12659/AOT.923536

19 January 2021 : Original article

Sirolimus Adverse Event Profile in a Non-Clinical Trial Cohort of Heart Transplantation Patients

Karim Sallam^12DEFG, Geetha P. Bhumireddy^2B, Vishnu D. Evuri^2B, Joshua P. Abella^2BC, Francois Haddad^3D, Hannah A. Valentine^3AD, Patricia K. Nguyen^32CDE, Michael X. Pham^4ADEG*

DOI: 10.12659/AOT.923536

Ann Transplant 2021; 26:e923536

Authors information Article notes Copyright and License information

Background Material and Methods Results Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Table 3 Multivariate logistic regression analysis of risk of adverse events.

	Odds ratio	Standard error	Z	p-Value
Group	5.30	2.07	4.26	<0.0001
Age	1.01	0.012	0.58	0.561
BMI	0.957	0.29	−1.46	0.146
Transplant reason	1.04	0.093	0.45	0.651
Induction	0.726	0.213	−1.09	0.276
CMV recipient	0.720	0.242	−0.98	0.329
CMV donor	1.86	0.667	1.73	0.084
Renal insufficiency	1.44	0.536	0.99	0.321
Sternotomy	0.540	0.199	−1.67	0.094
CAV	1.23	0.460	0.55	0.584
Cyclosporine	1.96	1.50	0.88	0.379
Tacrolimus	2.98	2.27	1.43	0.152
MMF	0.774	0.311	−0.64	0.524
Prednisone	0.797	0.319	−0.57	0.570
Early initiation post-transplant	1	0.00013	−3.14	0.002
Weight	1	0.0097	0.44	0.657
Diabetes	1.01	0.350	0.04	0.972

Back to the Article

Sirolimus Adverse Event Profile in a Non-Clinical Trial Cohort of Heart Transplantation Patients

Your Privacy